Clinical Trials Arena on MSN

Qihan Biotech begins subject dosing in Phase I/IIa study of QT-019B for rSLE

The study protocol comprises dose-expansion and dose-escalation phases and aims to assess the efficacy and safety of QT-019B.
TCTMD

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

Lepodisiran, a long-duration, short-interfering RNA (siRNA), dramatically slashed Lp(a) levels in a small, phase I study presented this weekend at the American Heart Association (AHA) 2023 Scientific ...
Business Wire

Vividion Therapeutics Doses First Patient in Phase I Study of RAS-PI3Kα Inhibitor for Treatment of Advanced Solid Tumors

VVD-159642, Vividion’s fourth clinical-stage program stemming from its chemoproteomics discovery platform, is designed to improve patient outcomes by inhibiting RAS-PI3Kα, a key signaling pathway ...
Clinical Trials Arena on MSN

Hutchmed begins Phase I HMPL-A251 clinical development programme

The clinical study is divided into two parts: a Phase I dose escalation stage and a Phase IIa dose expansion and optimisation stage.
The Manila Times

Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study

Single-ascending dose portion of study has successfully completed 2.5 and 7 mg / kg levelsDose dependent immunosuppressive ...